The battle of the fat jabs
The weight-loss drug market is experiencing explosive growth, propelling Eli Lilly to a trillion-dollar valuation. While Novo Nordisk faces share price declines, the competition intensifies for the next breakthrough in oral weight-loss medication, with investor behavior offering…